A Phase II Study of Chemo-Immunotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Big Ten Cancer Research Consortium BTCRC-LUN18-363
Latest Information Update: 13 Aug 2024
At a glance
- Drugs Carboplatin (Primary) ; Ceralasertib (Primary) ; Cisplatin (Primary) ; Durvalumab (Primary) ; Etoposide (Primary)
- Indications Carcinoma; Small cell lung cancer
- Focus Therapeutic Use
- 08 Aug 2024 Planned primary completion date changed from 1 Jul 2024 to 1 Aug 2024.
- 09 Jul 2024 Planned primary completion date changed from 1 Jun 2024 to 1 Jul 2024.
- 14 May 2024 Planned End Date changed from 1 May 2024 to 1 Sep 2024.